Exhibit 99.1 Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance -- Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 -- -- Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 -- CAMBRIDGE, Mass., August 1, 2024 – Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial resu ...

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). Expected Results of an Industry Player While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicappin ...

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 299779. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call. Blueprint Medi ...

-- Breadth of data across 7 presentations, including 4 oral, reflects continued leadership in advancing the understanding and treatment of systemic mastocytosis -- CAMBRIDGE, Mass., May 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced multiple upcoming datasets across two key conferences that reinforce the significant realworld burden of systemic mastocytosis (SM), and highlight the durable clinical outcomes of AYVAKIT®/AYVAKYT® (avapritinib) across the spectrum of the ...

AHN, or MCL, after at least one systemic therapy. In December 2023, the European Commission approved AYVAKYT for the treatment of adult patients with indolent SM with moderate to severe symptoms inadequately controlled on symptomatic treatment. These approvals in advanced SM were supported by our ongoing Phase 1 clinical trial in advanced SM, which we refer to as our EXPLORER trial, and our ongoing Phase 2 clinical trial in advanced SM, which we refer to as our PATHFINDER trial. The FDA's approval of AYVAKI ...

But we do see I think a potential kind of halo effect that on with the now the awareness of for the for ISM as our breadth of prescribing increases it's happening. You not just analogy, but also with a number of new hematology oncology prescribers as well who are activated and interested to get involved through ISM. Matt Biegler That's great. Thanks. Operator Your next question comes from the line of Ami Fadia from Needham. Ami, your line is open. Ami Fadia Mike Landsittel We'll be doing a lot of preclinica ...

First Quarter 2024 Financial Results Agenda AYVAKIT PERFORMANCE | --- | --- | --- | --- | --- | |-------|-------|-------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Q1 2024 FINANCIAL | | | | | | PERFORMANCE | | | | | | | | | | | | | | | | | | Mike Landsittel | | | | | | Chief Financial Officer | | | 2 3 INTRODUCTION Kate Haviland Chief Executive Officer THE POWERFUL MAST CELL Not for promotional use Forward-looking statements This presentation contains forward-looking statem ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.51%. A quarter ago, it was expected that this cancer drug developer would post a loss of $2.04 per share when it actually produced a loss of $1.82, delivering a surprise of 10.78%.Over the last four quarters, the co ...

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 -- "We delivered another very strong quarter in our launch of AYVAKIT in indolent systemic mastocytosis (ISM) and have entered 2024 in a position of stren ...

-- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 -- CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 202 ...